Quoin Pharmaceuticals Ltd ADR (QNRX) concluded trading on Thursday at a closing price of $0.41, with 60.65 million shares of worth about $24.87 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -33.05% during that period and on January 23, 2025 the price saw a loss of about -30.22%. Currently the company’s common shares owned by public are about 5.05M shares, out of which, 1.12M shares are available for trading.
Stock saw a price change of -29.66% in past 5 days and over the past one month there was a price change of -36.39%. Year-to-date (YTD), QNRX shares are showing a performance of -36.78% which decreased to -89.40% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.43 but also hit the highest price of $6.18 during that period. The average intraday trading volume for Quoin Pharmaceuticals Ltd ADR shares is 1.35 million. The stock is currently trading -30.94% below its 20-day simple moving average (SMA20), while that difference is down -35.01% for SMA50 and it goes to -36.81% lower than SMA200.
Quoin Pharmaceuticals Ltd ADR (NASDAQ: QNRX) currently have 5.05M outstanding shares and institutions hold larger chunk of about 3.27% of that.
The stock has a current market capitalization of $2.08M and its 3Y-monthly beta is at 1.75. It has posted earnings per share of -$4.08 in the same period. It has Quick Ratio of 3.02 while making debt-to-equity ratio of 0.00. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for QNRX, volatility over the week remained 20.85% while standing at 16.42% over the month.
Analysts are in expectations that Quoin Pharmaceuticals Ltd ADR (QNRX) stock would likely to be making an EPS of -0.43 in the current quarter, while forecast for next quarter EPS is -0.42 and it is -1.65 for next year. For the current quarter EPS, analysts have given the company a lowest target -0.43 which is -0.43 at the higher side of the target for the same. Stock’s fiscal year EPS is expected to rise by 78.42% while it is estimated to increase by 29.01% in next year.
